Avillion has announced the appointment of Dr David Chiswell OBE as a non-executive director of Bond 2 Development 2 GP – the General Partner of Bond Avillion 2, the Avillion entity that enters into the co-development agreements with pharma partners.
Dr Chiswell has over 30 years’ experience in the biotechnology industry having co-founded Cambridge Antibody Technology (CAT) in 1990, serving as CEO from 1996 to 2002. Since leaving CAT in 2002, Dr Chiswell has focused on the development of early stage biotechnology companies, having previously served as a director of Arakis, non-executive chairman of Sosei, Arrow Therapeutics, Daniolabs, Nabriva Therapeutics and Kymab. He currently serves as chairman of Albireo Pharma.
